GlassScriptPhysician profile
Sarah Samimi Field
NPI 1053532366
$13,545.40
in general payments reported to CMS, 2019-2025
26 companies · $4,286 in 2025
The $4,286 reported for 2025 was more than what 85% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2020: $3,254 · 2021: $2,638 · 2022: $488 · 2023: $605 · 2024: $951 · 2025: $4,286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,600 · Food and Beverage: $2,044 · Education: $159 · Travel and Lodging: $38.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,600.00 |
| Food and Beverage | $2,043.93 |
| Education | $158.55 |
| Travel and Lodging | $38.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $3,762.64 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $2,467.53 | 2020-2025 | Takhzyro, Eohilia |
| Regeneron Healthcare Solutions, INC. | $2,423.31 | 2019-2025 | Dupixent |
| Genzyme Corporation | $1,803.25 | 2019-2025 | |
| Csl Behring | $797.50 | 2019-2025 | Hizentra |
| Shire North American Group INC | $382.63 | 2019 | |
| Novartis Pharmaceuticals Corporation | $305.64 | 2019-2025 | |
| Pfizer INC. | $275.09 | 2019-2025 | |
| Genentech USA, INC. | $256.48 | 2022-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $183.28 | 2019-2021 | |
| Optinose US, INC. | $159.13 | 2019-2024 | |
| Glaxosmithkline, LLC. | $134.97 | 2019-2024 | Nucala, Trelegy Ellipta |
| Grifols USA, LLC | $111.24 | 2022-2025 | Xembify |
| Regeneron Pharmaceuticals, INC. | $107.03 | 2025 | Dupixent |
| Pharming Healthcare, INC. | $87.13 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $62.42 | 2019-2020 | |
| Amgen INC. | $61.71 | 2021-2022 | |
| Abbvie INC. | $59.59 | 2022-2023 | |
| Azurity Pharmaceuticals, INC. | $27.58 | 2025 | Alvesco |
| Biocryst US Sales Co., LLC | $22.03 | 2022 | |
| Leo Pharma INC. | $21.39 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.15 | 2021 | |
| Octapharma USA, INC. | $14.68 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Field listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.